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Abstract
Background: Asthma is a syndrome composed of heterogeneous disease entities. Although it is agreed that proper
asthma endo-typing and appropriate type-specific interventions are crucial in the management of asthma, little data
are available regarding pediatric asthma.
Methods: We designed a cluster-based, prospective, observational cohort study of asthmatic children in Korea (Korean
childhood Asthma Study [KAS]). A total of 1000 Korean asthmatic children, aged from 5 to 15 years, will be enrolled at
the allergy clinics of the 19 regional tertiary hospitals from August 2016 to December 2018. Physicians will verify the
relevant histories of asthma and comorbid diseases, as well as airway lability from the results of spirometry and
bronchial provocation tests. Questionnaires regarding subjects’ baseline characteristics and their environment, self-
rating of asthma control, and laboratory tests for allergy and airway inflammation will be collected at the time of
enrollment. Follow-up data regarding asthma control, lung function, and environmental questionnaires will be
collected at least every 6 months to assess outcome and exacerbation-related aggravating factors. In a subgroup of
subjects, peak expiratory flow rate will be monitored by communication through a mobile application during the
overall study period. Cluster analysis of the initial data will be used to classify Korean pediatric asthma patients into
several clusters; the exacerbation and progression of asthma will be assessed and compared among these clusters. In a
subgroup of patients, big data-based deep learning analysis will be applied to predict asthma exacerbation.
Discussion: Based on the assumption that asthma is heterogeneous and each subject exhibits a different subset of risk
factors for asthma exacerbation, as well as a different disease progression, the KAS aims to identify several asthma
clusters and their essential determinants, which are more suitable for Korean asthmatic children. Thereafter we may
suggest cluster-specific strategies by focusing on subjects’ personalized aggravating factors during each exacerbation
episode and by focusing on disease progression. The KAS will provide a good academic background with respect to
each interventional strategy to achieve better asthma control and prognosis.
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Background
Asthma has been characterized as a chronic inflammatory
airway disease with bronchial hyperresponsiveness to a
variety of stimuli, as well as variable airflow obstruction
that is reversible either spontaneously or with treatment
[1]. Control of airway inflammation has been a mainstay
of asthma treatment, particularly control of eosinophilic
inflammation mediated by immunoglobulin E (IgE) pro-
duction in response to a specific or non-specific stimulus
[2, 3]. Asthma guidelines recommend the use of inhaled
corticosteroid to control airway inflammation and to re-
duce episodes of asthma exacerbation that require add-
itional systemic glucocorticoid administration and/or
beta-agonist inhalation [4–6]. However, airway inflamma-
tion is not always eosinophilic, and airflow obstruction
sometimes occurs without airway inflammation [7].
Therefore, asthma is now regarded as a syndrome com-
prising heterogeneous disease entities with variable re-
sponses to selected therapies [8].
Asthma can be classified in various ways [9]. Atopy
has long been utilized as a criterion to classify pediatric
asthma, and it appears to be a reasonable approach. In-
trinsic asthma shows no clinical or serological evidence
of IgE-mediated allergy to common environmental
agents; moreover, it presents different immunopathology
and lung function outcomes to extrinsic asthma [10, 11].
Atopy or high IgE level is an important determinant of
asthma inception and persistence; thus, it is known as
the intermediate phenotype of asthma [12]. However,
simple classification into intrinsic or extrinsic asthma
cannot explain various asthma phenotypes that are en-
countered in the clinic. In adult asthma, latent class ana-
lysis has succeeded in revealing various asthma
phenotypes [13]. Furthermore, the addition of further
variables regarding asthma pathophysiology can help to
evaluate various asthma endotypes [14]. This approach
is critically important, because asthma control and final
outcome may be associated with these endotypes; they
may ultimately enable the provision of a patient-tailored
management plan for asthma [15].
In addition to the progress in adult studies, endotyping
of pediatric asthma has now been documented in a few
reports. However, most studies that have presented
asthma clusters and differences in treatment responses
included participants in the Severe Asthma Research
Program [16–18]. Other researchers are now massively
clustering clinical information [19], or working to merge
cohort data (i.e., Childhood Asthma Management Pro-
gram, CAMP) with genetic information [20], their re-
sults have not been replicated for the subsequent studies
yet. Furthermore, ethnic and environmental factors can
exhibit significant effects, but a data archiving program
of Korean asthmatic children does not exist. From this
perspective, a prospective study must be launched to
archive clinical characteristics, environmental factors,
asthma control status, allergy profile, lung function (in-
cluding bronchial responsiveness, candidate biomarkers,
and treatment responses), and their changes over time.
We designed a cluster-based, prospective, observa-
tional cohort study of asthmatic children in Korea. We
will gather information regarding Korean pediatric
asthma patients, classify them by using cluster analysis
(include laboratory and other potential biomarkers) [21],
trace their changes over time, and compare asthma ex-
acerbation and progression between clusters (Fig. 1). We
will ultimately explore factors that may help us to iden-
tify subjects’ asthma endotypes and appropriate strategy
to prohibit progression to adult asthma.
Methods/design
Study design
KAS is an ongoing, real-world, observational pro-
spective cohort study that involves 1000 asthmatic
children at 19 centers in Korea (Fig. 2). Researchers
invite subjects to participate in the study at the clinic:
if they agree to participate, researchers gather baseline
characteristics via a set of questionnaires, pulmonary
function data including bronchial responsiveness,
blood samples for allergies, and additional potential
variables. In a subset of children (n = 400), we distrib-
uted peak-flow meters and educated caregivers
regarding measurement of peak-flow, as well as
reporting peak-flow results and daily symptoms
through a mobile application. Subjects’ treatment re-
sponses, including levels of asthma control and epi-
sodes of exacerbation, lung function, and changes in
body physics and environmental factors are evaluated
at least every 6 months during regular visits. Bron-
chial hyperresponsiveness (BHR) and atopy are mea-
sured every 3 years during the study period. Changes
in all above variables are compared between clusters
at baseline and every 3 years during the study period
(Table 1).
Study population and setting
To represent real-world asthmatic children in Korea, all
children with suspected asthma are considered for study
enrollment when they visit the allergy clinic at each re-
gional center. When they meet inclusion/exclusion cri-
teria, written consent is obtained from both patient and
caregiver. Subjects are regularly followed up with various
asthma treatments determined by each pediatric allergist
according to the NAEPP asthma guideline [4]. When
subjects are stable and show no asthma exacerbation for
at least 1 month with their current asthma management,
their lung function and airway inflammation are evalu-
ated and set as their baseline values.
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Fig. 1 Conceptual diagram of Korean childhood Asthma Study. Hierarchical clustering of the initial data will classify pediatric asthma into several
clusters; the archived data will show differences in exacerbation and asthma progression among Korean childhood asthma clusters
Fig. 2 The 19 hospitals participating in the Korean childhood Asthma Study (KAS). The original shapefile of the map is from Wikimedia Commons
(South_Korean_presidential_election_2007.svg licensed with Cc-by-sa-3.02012–11-23 T04:30:57Z)
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Inclusion and exclusion criteria of study subjects
When subjects 5–15 years old report experiencing typical
symptoms of asthma (i.e., wheezing, dyspnea, and chronic
cough) within the most recent 12-month period, they are
included in this cohort if they show either an elevated
bronchodilator response (≥12% increase of forced expira-
tory volume in 1 s [FEV1] 15min after inhaling 200 mcg
of salbutamol) or BHR (a < 16mg/mL dose of provocative
methacholine concentration causing a 20% fall in FEV1
[PC20] or a < 635mg dose of provocative mannitol weight
causing a 15% fall in FEV1 [PD15]) [22, 23]. Subjects are
excluded from this cohort if they exhibit interstitial lung
diseases or pulmonary neoplasms. If subjects are already
diagnosed with bronchopulmonary dysplasia or bronchio-
litis obliterans, they are excluded at the enrollment stage;
however, if they are newly diagnosed during follow-up,
they remain in the cohort and are separately analyzed.
Data collection
Questionnaires
At the time of enrollment, we ask patients and/or their
caregivers to complete questionnaires regarding both the
disease and the patients’ environment. The former in-
cludes asthma onset, associated allergies, past medica-
tion, level of control, compliance, familial history of
asthma/allergic diseases, smoking exposure, and aggra-
vating factors. The latter includes subjects’ housing and
exposures to fine particles, yellow dusts, surrounding
facilities, indoor exposure to dust mites, fungus, and
cockroaches [24]. For middle school children, separate
questionnaires are given to both children and their
caregivers; for elementary school children, question-
naires are solely given to their caregivers. These ques-
tionnaires are given every 6 months thereafter.
Asthma control test
We evaluate subjects’ level of asthma control from the
time of enrollment and during regular follow-up. Child-
hood Asthma Control Test (c-ACT) is used for subjects
aged 5 to 11, and the Asthma Control Test is provided
for those aged 12 and older [25, 26].
Physicians’ assessment
At the time of enrollment and during follow-up, subjects
grade their (or their children’s) puberty status by check-
ing an illustration of the Tanner stage grading system
[27]. Physicians verify current asthma, allergic rhinitis,
atopic dermatitis, and food allergies. They confirm the
absence of bronchopulmonary dysplasia or bronchiolitis
obliterans by reviewing subjects’ medical records and
asking them detailed questions. Subjects’ asthma severity
is also assessed in accordance with the Expert Panel Re-
port 3 asthma guideline, which is used to determine the
types and doses of subjects’ controller medications [4].
Blood tests
Blood is withdrawn to evaluate subjects’ blood cell
counts, eosinophil fraction, level of total serum IgE, and
amount of C-reactive protein. Additional blood samples
are acquired to measure gene expression and cytokine
levels, and to obtain DNA.
Table 1 Overview of data variables and collection schedule in Korean childhood Asthma Study (KAS)
Enrollment (month) Scheduled visits for subjects (month)
0 6, 12, 18, 24, 30 36 42, 48, 54, 60, 66 72
Questionnaire
regarding asthma
V V V V V
Questionnaire regarding environment V V V V V
ACT/C-ACT V V V V V
Individual case record V V V V V
WBC, CRP, Eosinophil count, Total IgE V V V




Methacholine PC20 or Mannitol PD15 V V V
FeNO V V V





App installation and usage instruction Confirmation of input and instruction
Abbreviations: ACT Asthma control test, C-ACT Childhood asthma control test, WBC White blood cell, CRP C-reactive protein, BD Bronchodilator, App Application,
FEV1 Forced expiratory volume in 1 s, FVC Forced volume vital capacity, MMEF Maximal mid-expiratory flow, PC20 Provocative concentration of methacholine
causing a 20% fall in FEV1, PD15 Provocative dose of mannitol causing a 15% fall in FEV1, FeNO Fractional exhaled nitric oxide
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Skin prick test
At each hospital, a skin prick test on a battery of 18 in-
halant allergens is performed to assess subjects’ allergen
sensitization: two dust mite allergens (D. pteronyssinus
and D. farina), three mold allergens (Alternaria, Asper-
gillus, and Cladosporium), two animal dander allergens
(dog and cat), a cockroach allergen, and ten pollen aller-
gens (oak, alder, hazel, beech, birch, rye grass, ragweed,
hop, timothy, and mugwort). We use the modified
method of Pepys, and the histamine and saline serve as
respective positive and negative controls [28]. Subjects
are defined as “sensitized” when a positive reaction,
wheal size exceeding 3 mm and exceeding that of the
positive control, is present for at least one allergen.
Lung function test and bronchial provocation test
Spirometry is performed according to international stan-
dards [29]. The forced vital capacity, FEV1, and the max-
imal mid-expiratory flow are measured before and 15
min after inhaling 2–4 puffs of salbutamol. Lung func-
tion is measured when subjects are stable with good
asthma control.
Any medication that may influence lung function is
withheld for 4 weeks before evaluating BHR. Methacho-
line challenge is conducted in accordance with ATS
protocol [22]. Fresh solutions of methacholine are seri-
ally diluted in buffered saline solution at concentrations
of 0, 0.0625, 0.25, 1, 4, and 16 mg/mL. Provocative con-
centrations of methacholine causing a 20% fall in FEV1
from baseline are interpolated and set as a parameter of
BHR. In some cases, the mannitol provocation test may
be substituted for methacholine challenge. Dry pow-
dered mannitol (Aridol®) is sequentially inhaled, follow-
ing the method suggested by Anderson et al. [23]. The
provocative dose of mannitol causing a 15% fall in FEV1
of < 635 mg is regarded as BHR.
Self-assessed peak expiratory flow rate
Subjects are guided to assess their peak expiratory flow
rate (PEFR) with their supplemental mini-Wright peak
flow meter. They are instructed to blow the mouthpiece
as quickly and as hard as possible without putting their
tongue in front of the mouthpiece [29]. The best value
from three big blows is recorded as their PEFR.
Fraction of exhaled nitric oxide
To measure subjects’ airway eosinophilic inflammation,
their fraction of exhaled nitric oxide (FeNO) is measured
by a hand-held device (NIOX MINO® [Aerocrine, Solna,
Sweden] or NOBreath® [Bedfont Scientific, Maidstone,
UK]) at every hospital. The ATS/ERS guideline is
adopted for the standard procedure [30]. Briefly, FeNO
is assessed during a single slow breath of at least 10
cmH2O against resistance and an expiratory flow rate of
50 mL/s. Exhalations are repeated up to three times and
the mean is recorded as the subject’s FeNO level.
Mobile application
For those with Android devices, a mobile application is
used to monitor subjects’ asthma exacerbation during
the overall study period. Subjects are instructed to rec-
ord daily symptoms (wheezing, chest tightness, dyspnea,
night time symptoms, and limitation of daily activities),
PEFR results, rescue medication use, unscheduled visit
to a local clinic or emergency room, and need for admis-
sion until they were fully recovered.
Data quality control
All individual case records (ICRs) are sent to the main
data coordinating center in the Asan Medical Center,
where a trained nurse verifies all ICR values and uploads
them into the iCReaT (Internet based Clinical Research
and Trial management system). The iCReaT is a
web-based electronic data capture system developed and
operated by a government organization, the Korea Cen-
ters for Disease Control and Prevention. Data entry to
iCReaT is restricted to main center personnel. Another
data manager regularly oversees the data input process
and monitors the data integrity by scanning for typo-
logical errors and missing values, as well as by mining
outliers and reviewing ICRs and source documents. The
authors formed a data management committee com-
posed of key researchers, data managers, and the coord-
inator in the main center. The committee monitors the
entire process biannually, reviews queries received, dis-
cusses plans to secure the data integrity, and provides
feedback to each researcher with relevant issues.
Outcome assessments
Follow-up data regarding asthma outcome are obtained
from the physicians’ record and laboratory results from
each institution, as well as from questionnaires from pa-
tients/caregivers. Supplemental information imbedded to
the national Health Insurance Review and Assessment
service (HIRA) system is assessed to evaluate medical fa-
cility utilization among the enrolled institutions.
Asthma exacerbations are defined as episodes of pro-
gressive increase in shortness of breath, cough, wheezing,
chest tightness, or a combination of these symptoms [31];
here, we practically define them as asthma attacks that re-
sult in medical interventions, including hospitalization,
unscheduled visits (physician or emergency department),
or prescription of oral corticosteroids (in patients who are
not already on regular oral corticosteroids) [32]. Symp-
toms that completely disappear immediately after a single
dose of inhaled salbutamol are not considered exacerba-
tion. In the subset of subjects with mobile applications,
asthma exacerbation is also defined as reduction of PEFR
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by more than 20% from the individual maximum level in
the presence of asthma symptoms.
Uncontrolled asthma is defined as at least one of
the following, in accordance with modified ERS/ATS
guidelines [33]: Poor symptom control of ACT or
c-ACT < 20; two or more severe exacerbations requir-
ing systemic corticosteroid for more than 3 days in
the previous year; at least one serious exacerbation
requiring hospitalization, ICU stay, or mechanical
ventilation in the previous year; and/or airflow limita-
tion of a FEV1 < 80% after bronchodilator.
Severe asthma is defined according to ERS/ATS
guidelines as asthma that requires treatment with
suggested medications for GINA steps 4–5 asthma for
the previous year, or systemic corticosteroid for ≥50%
of the previous year to prevent it from becoming “un-
controlled,” or asthma that remains “uncontrolled”
despite such therapy [33].
Clinical asthma remission is a primary outcome, and it
is defined as the absence of asthma symptoms for ≥2
years and no asthma medication use for ≥2 years [34].
Asthma persistence is defined as the presence of asthma
symptoms within 1 year or the use of any asthma medi-
cation in the previous year.
Laboratory changes in lung function, BHR, and atopic
sensitization, according to the asthma clusters, are our
primary interests. In terms of lung function, percentage
predicted values are designated as comparing parame-
ters. Changes of more than two doubling doses in PC20
or PD15 are interpreted as significant [35]. Negative or
positive conversion among a panel of allergens is judged
to be significant.
Current status
As of August 2018, a total of 923 asthmatic children
were enrolled in KAS. Among them, two have with-
drawn from the study and two were lost to follow up.
Thus, 919 children are currently enrolled in KAS
(Fig. 3).
Statistical analysis
Cluster analysis will be used via hierarchical clustering
algorithm with Ward’s minimum variance method. Hier-
archical cluster analysis generally comprises cluster for-
mation by grouping closely related individuals in an
individual manner. Based on the measure of the distance
between the clusters, pairs are merged with each other
at each step; ultimately, “n” objects are grouped together
to form a cluster. Dendrograms will be used to deter-
mine the number of clusters. To test for differences be-
tween clusters, ANOVA and χ2 tests will be performed.
All above analyses will be conducted by using SAS ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA). In the sub-
set of subjects with the mobile application, a big
data-based deep learning analysis will be conducted to
predict asthma exacerbation based on the spatiotempo-
ral correlation between the asthmatic patient’s medical
records, daily PEFR data, and environmental factors (in-
cluding daily air pollution, pollen, and meteorological
data).
Ethical considerations
Ethical approval has been granted by the Institutional Eth-
ics Committee of each participant institution. The study
was approved by the Institutional Review Boards of Asan
Medical Center (IRB No. 2016–0914), Seoul National Uni-
versity Hospital (IRB No. 1607–165-779), Pusan National
University Yangsan Hospital (IRB No. 05–2016-121), Inha
University Hospital (IRB No. 2016–07–016-008), Seoul
National University Bundang Hospital (IRB No. 10–
2017-036), Chonnam National University Hospital (IRB
No. 2017–201), Korea University Anam Hospital (IRB No.
2015 AN 0310), Soonchunhyang University Hospital Seoul
(IRB No. 2017–01–011-002), Bucheon St. Mary’s Hospital
(IRB No. HC16SNMI0056), Sungkyunkwan University
Samsung Changwon Hospital (IRB No. 2017–02–
006-001), Kangdong Sacred Heart Hospital (IRB No.
2016–12–007-001), The Catholic University of Korea,
Uijeongbu St. Mary’s Hospital (IRB No. UC16ONMI0113),
Chungbuk National University Hospital (IRB No. 2016–
09-003), Dankook University Hospital (IRB No. 2017–
02-013), Korea University Guro Hospital (IRB No.
2016GR0336), Seoul Paik Hopsital, Inje University (IRB
No. 2016–314), Gangnam CHA Medical Center (IRB No.
GCI-16-37), National Health Insurance Service Ilsan Hos-
pital (IRB No. NHIMC 2017–02-008), Soonchunhyang
Fig. 3 Current status of Korean childhood Asthma Study (KAS). A
total of 923 asthmatic children have consented to participate in the
study. Of these, two withdrew their consent and another two were
lost to follow-up. Currently, the study cohort includes 919 children
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University School of Medicine, Bucheon (IRB No 2016–
08–007-009).
Discussion
We have launched a prospective observational disease
cohort for asthmatic children in Korea. Based on the
assumption that asthma is heterogeneous, the KAS
gathers demographic, clinical, environmental, and la-
boratory variables that might affect asthma severity,
and endeavors to determine its exacerbation and pro-
gression. Children’s asthma subtypes and their subset
of risk factors of asthma exacerbation can subse-
quently be inferred by cluster analysis. Because this
study archives both cross-sectional and longitudinal
data, we can also evaluate relationships among vari-
ables and their changes over time. We can focus on
asthma in a very specific group of children, including
either adolescent or severe asthmatic patients. The
KAS aims to eventually suggest a personalized strat-
egy to achieve better asthma control and best
prognosis.
Prior to enrollment, we exclude subjects with a prior
history of BPD or BO. However, we do not exclude sub-
jects who are eventually diagnosed with BPD or BO
from the ongoing KAS study, because they are not easily
discernable from childhood asthma at baseline and they
may constitute a subset of childhood asthma patients in
the real world [36].
The primary goal of the KAS is to archive information
regarding the clinical and environmental characteristics
of Korean asthmatic children, along with their pulmon-
ary function and allergy status. Changes in these vari-
ables over time are also of interest. The authors hope to
evaluate the following topics by analyzing the archived
data:
1. Asthma clusters in Korean children
2. Nationwide distribution of asthma clusters and
regional characteristics of Korean childhood asthma
3. Patterns of airway microbiome across asthma
clusters
4. Comparisons of microRNA expression patterns
across asthma clusters as exploratory biomarkers
5. Characteristics of severe asthma in Korean children
6. Characteristics of asthma in adolescents, compared
with asthma in younger children
7. Characteristics of specific asthma phenotypes (e.g.,
mold-sensitized asthmatic children) in a subgroup
of the study population
8. Changes in asthma severity over time and their
determinants
9. Changes in lung function and BHR over time,
with particular regard to asthma clusters
10. Differences in asthma outcome and treatment
response among clusters
11. Environmental risk factors of asthma exacerbation
with respect to asthma clusters
12. Impact of patient-tailored environmental intervention
on asthma control as a spin-off trial for a small
number of selected subjects
13. Determinants and prognostic factors of asthma
remission in Korean children
Based on the assumption that asthma is heterogeneous
and that each subject will exhibit a different subset of
risk factors for asthma exacerbation and progression, the
KAS first aims to identify several asthma clusters and
their essential determinants, which are more applicable
to Korean asthmatic children. Thereafter, our analysis
may suggest cluster-specific strategies by focusing on
subjects’ personalized aggravating factors during each
exacerbation episode. The KAS will provide a good aca-
demic background to understand asthma pathophysi-
ology in children and will help to identify individualized
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